Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2018 | Transplantation for PNH?

Regis Peffault de Latour • 18 Mar 2018
EBMT 2018
Non-Malignant Paroxysmal Nocturnal Hemoglobinuria

From the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, held in Lisbon, Portugal, Régis Peffault de Latour, MD, PhD, of Saint Louis Hospital, Paris, France, discusses the treatments currently available for treating paroxysmal nocturnal hemoglobinuria (PNH). He states how classic PNH can be treated effectively with complement blockers, thus transplant tends to not be an option. However, with PNH associated with aplastic anemia, transplantation is the only curative treatment available with minimal toxicities and a successful outcome.

More from Regis Peffault de Latour

2:55
RACE: evaluating eltrombopag in severe aplastic anemia
Regis Peffault de Latour • 3 Sep 2020
1:17
Overview of HSCT and GvHD at EBMT
Regis Peffault de Latour • 3 Sep 2020
2:01
Eltrombopag for aplastic anaemia in Europe
Regis Peffault de Latour • 1 Sep 2020
2:21
LNP023 for paroxysmal nocturnal hemoglobinuria
Regis Peffault de Latour • 2 Sep 2020

Related Videos

2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals